Hayakawa Fumihiko
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine.
Rinsho Ketsueki. 2016 Mar;57(3):230-7. doi: 10.11406/rinketsu.57.230.
There was no significant improvement in the treatment of adult acute lymphoblastic leukemia (ALL) in the 1ast two decades of the 20th century. However, remarkable improvements in survival have been achieved since the beginning of the 21st century, employing new treatments such as those for AYA ALL based on pediatric protocols and Ph+ ALL chemotherapies combining imatinib with other treatments. This review introduces the frontline therapies for adult ALL and discusses the current perspectives on the treatment of this malignancy.
在20世纪的最后二十年里，成人急性淋巴细胞白血病（ALL）的治疗没有显著改善。然而，自21世纪初以来，采用基于儿科方案的AYA ALL治疗方法以及将伊马替尼与其他治疗方法相结合的Ph+ ALL化疗等新治疗方法，生存率已取得显著提高。本文综述介绍了成人ALL的一线治疗方法，并讨论了目前对这种恶性肿瘤治疗的观点。
